Crediverso is a financial products advisor for the US Latino community.
Crediverso is a financial products advisor for the US Latino community.
Drinkers should still follow government guidelines and take precautions against Covid-19 even when outside enjoying beer gardens, an expert has said. Professor Adam Finn, a member of the Joint Committee on Vaccination and Immunisation , said Britons should still continue to socially distance in the “coming weeks and months” despite the success of the UK vaccine programme. Prof Finn’s comments came as the country entered phase two of the Government’s roadmap out of lockdown, with pub beer gardens and restaurants are now able to serve customers outdoors, and non-essential retailers and hairdressers also allowed to reopen.
The "World - Tents (Including Caravan Awnings) - Market Analysis, Forecast, Size, Trends and Insights" report has been added to ResearchAndMarkets.com's offering.
Prolific (and generally accurate) camera leaker Nokishita has just tweeted an image that appears to show an EOS R3 camera.
Ingevity will hold a live webinar to discuss activated carbon’s runway with the internal combustion engine on April 14, 2021, at 10 a.m. (EST).
Russian metals producer Nornickel said on Tuesday it will boost output of nickel products at its Harjavalta plant in Finland as it bets on the expanding market for battery materials needed for electric vehicles (EV). Finland's state mining investment firm Finnish Minerals Group, German chemicals giant BASF and Finnish utility Fortum are among companies currently forming an EV battery cluster in Finland.
The "Infant Formula Global Market Insights 2020, Analysis and Forecast to 2025, by Manufacturers, Regions, Technology, Application, Product Type" report has been added to ResearchAndMarkets.com's offering.
Dublin, April 13, 2021 (GLOBE NEWSWIRE) -- The "Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report 2021" report has been added to ResearchAndMarkets.com's offering. The main objectives of this report are to describe the current status of iPSC research, patents, funding events, industry partnerships, biomedical applications, technologies, and clinical trials for the development of iPSC-based therapeutics. Since the discovery of induced pluripotent stem cells (iPSCs) a large and thriving research product market has grown into existence, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number.Therapeutic applications of iPSCs have surged in recent years. 2013 was a landmark year in Japan because it saw the first cellular therapy involving the transplant of iPSCs into humans initiated at the RIKEN Center in Kobe, Japan. Led by Masayo Takahashi of the RIKEN Center for Developmental Biology (CDB), it investigated the safety of iPSC-derived cell sheets in patients with macular degeneration. In another world-first, Cynata Therapeutics received approval in 2016 to launch the world's first formal clinical trial of an allogeneic iPSC-derived cell product (CYP-001) for the treatment of GvHD. Riding the momentum within the CAR-T field, Fate Therapeutics is developing FT819, its "off-the-shelf" iPSC-derived CAR-T cell product candidate. Numerous physician-led studies using iPSCs are also underway in Japan, a leading country for basic and applied iPSC applications.iPS Cell Market CompetitorsToday, FUJIFILM CDI has emerged as one of the largest commercial players within the iPSC sector. FUJIFILM CDI was founded in 2004 by Dr. James Thomson at the University of Wisconsin-Madison, who in 2007 derived iPSC lines from human somatic cells for the first time ever. The feat was accomplished simultaneously by Dr. Shinya Yamanaka's lab in Japan.In 2009, ReproCELL, a company established as a venture company originating from the University of Tokyo and Kyoto University, made iPSC products commercially available for the first time with the launch of its human iPSC-derived cardiomyocytes, which it called ReproCario.A European leader within the iPSC market is Ncardia, formed through the merger of Axiogenesis and Pluriomics. Founded in 2001, Axiogenesis initially focused on generating mouse embryonic stem cell-derived cells and assays, but after Yamanaka's iPSC technology became available, it became the first European company to license it in 2010. Ncardia's focus is on preclinical drug discovery and drug safety through the development of functional assays using human neuronal and cardiac cells. In total, at least 68 distinct market competitors now offer various types of iPSC products, services, technologies and therapies. iPS Cell CommercializationMethods of commercializing induced pluripotent stem cells (iPSCs) are diverse and continue to expand. iPSC cell applications include, but are not limited to: Research Products: Market competitors provide iPSC specific tools to scientists worldwide, including human iPSC lines and differentiated cell types, as well as optimized reagents, protocols, differentiation kits, and more.Drug Development & Discovery: iPSCs have the potential to transform drug discovery by providing physiologically relevant cells for compound identification, target validation, compound screening, and tool discovery.Cellular Therapy: iPSCs are being explored in a diverse range of cell therapy applications for the purpose of reversing injury or disease.Toxicology Screening: iPSCs can be used for toxicology screening, which is the use of stem cells or their derivatives (tissue-specific cells) to assess the safety of compounds or drugs within living cells.Personalized Medicine: The use of techniques such as CRISPR enables precise, directed the creation of knock-outs and knock-ins (including single-base changes) in many cell types. Pairing iPSCs with genome editing technologies has added a new dimension to personalized medicine.Disease Modelling: By generating iPSCs from patients with disorders of interest and differentiating them into disease-specific cells, iPSCs can effectively create disease models "in a dish."Stem Cell Banking: iPSC repositories provide researchers with the opportunity to investigate a diverse range of conditions using iPSC-derived cell types produced from both healthy and diseased donors.Other Applications: Other applications for iPSCs include areas like tissue engineering, 3D bioprinting, clean meat production, wildlife conservation, and more. Since the discovery of iPSC technology in 2006, significant progress has been made in stem cell biology and regenerative medicine. New pathological mechanisms have been identified and explained, new drugs identified by iPSC screens are in the pipeline, and the first clinical trials employing human iPSC-derived cell types have been initiated. Key Topics Covered: 1. REPORT OVERVIEW1.1 Statement of the Report1.2 Executive Summary 2. INTRODUCTION2.1 Discovery of iPSCs2.2 Barriers in iPSC Application2.3 Timeline and Cost of iPSC Development2.4 Current Status of iPSCs Industry2.4.1 Share of iPSC-based Research within the Overall Stem Cell Industry2.4.2 Major Focuses of iPSC Companies2.4.3 Commercially Available iPSC-Derived Cell Types2.4.4 Relative Use of iPSC-Derived Cell Types in Toxicology Testing Assays2.4.5 Toxicology/Safety Testing Assays using iPSC-Derived Cell Types2.5 Currently Available iPSC Technologies2.6 Advantages and Limitations of iPSCs Technology 3. HISTORY OF INDUCED PLURIPOTENT STEM CELLS (IPSCS)3.1 First iPSC generation from Mouse Fibroblasts, 20063.2 First Human iPSC Generation, 20073.3 Creation of CiRA, 20103.4 First High-Throughput screening using iPSCs, 20123.5 First iPSCs Clinical Trial Approved in Japan, 20133.6 The First iPSC-RPE Cell Sheet Transplantation for AMD, 20143.7 EBiSC Founded, 20143.8 First Clinical Trial using Allogeneic iPSCs for AMD, 20173.9 Clinical Trials for Parkinson's disease using Allogeneic iPSCs, 20183.10 Commercial iPSC Plant SMaRT Established, 20183.11 First iPSC Therapy Center in Japan, 2019 4. RESEARCH PUBLICATIONS ON iPSCS4.1 Categories of Research Publications4.2 Percent Share of Published Articles by Disease Type4.3 Number of Articles by Country 5. IPSCS: PATENT LANDSCAPE5.1 Timeline and Status of Patents5.2 Patent Filing Destinations5.2.1 Patent Applicant's Origin5.2.2 Top Ten Global Patent Applicants5.2.3 Collaborating Applicants of Patents5.3 Patent Application Trends iPSC Preparation Technologies5.4 Patent Application Trends in iPSC Differentiation Technologies5.5 Patent Application Trends in Disease-Specific Cell Technologies 6. CLINICAL TRIALS INVOLVING iPSCS6.1 Current Clinical Trials Landscape6.1.1 Clinical Trials Involving iPSCs by Major Diseases6.1.2 Clinical Trials Involving iPSCs by Country 7. FUNDING FOR iPSCs7.1 Value of NIH Funding for iPSCs7.1.1 NHI's Intended Funding Through its Component Organizations in 20207.1.2 NIH Funding for Select Universities for iPSC Studies7.2 CIRM Funding for iPSCs 8. GENERATION OF INDUCED PLURIPOTENT STEM CELLS: AN OVERVIEW8.1 Reprogramming Factors8.2 Overview of Four Key Methods of Gene Delivery8.3 Comparative Effectiveness of Different Vector Types8.4 Genome Editing Technologies in iPSCs Generation 9. HUMAN iPSC BANKING9.1 Cell Sources for iPSCs Banking9.2 Reprogramming methods used in iPSC Banking9.3 Workflow in iPSC Banks9.4 Existing iPSC Banks 10. BIOMEDICAL APPLICATIONS OF iPSCS10.1 iPSCs in Basic Research10.2 iPSCs in Drug Discovery10.3 iPSCs in Toxicology Studies10.4 iPSCs in Disease Modeling10.5 iPSCs within Cell-Based Therapies 11. OTHER NOVEL APPLICATIONS OF iPSCS11.1 iPSCs in Tissue Engineering11.2 iPSCs in Animal Conservation11.3 iPSCs and Cultured Meat 12. DEAL-MAKING WITHIN THE iPSC SECTOR12.1 License Agreement between FUJIFILM Cellular Dynamics and Sana12.2 Century Therapeutics Closes $160 Million Series C Financing12.3 Bluerock Gains Access to Ncardia's iPSCs-derived Cardiomyocytes12.4 Fate Therapeutics' Deal with Janssen Biotech12.5 Century Therapeutics Acquires Empirica Therapeutics12.6 $250 Million Raised by Century Theraputics12.7 BlueRock Therapeutics Launched with $225 Million12.8 Collaboration between Allogene Therapeutics and Notch Therapeutics12.9 Acquisition of Semma Therapeutics by Vertex Therapeutics12.10 Evotec's Extended Collaboration with BMS12.11 Licensing Agreement between Allele Biotechnology and Astellas12.12 Codevelopment Agreement between Allele & SCM Lifesciences12.13 Fate Therapeutics Signs $100 Million Deal with Janssen12.14 Allele's Deal with Alpine Biotherapeutics12.15 Editas and BlueRock's Development Agreement 13. MARKET OVERVIEW13.1 Global Market for iPSCs by Geography13.2 Global Market for iPSCs by Technology13.3 Global Market for iPSCs by Biomedical Application13.4 Global Market for iPSCs by Cell Types3.5 Market Drivers13.6 Market Restraints 14. COMPANY PROFILES Addgene, Inc.Aleph FarmsAllele Biotechnology and Pharmaceuticals, Inc.ALSTEM, INC.American Type Culture Collection (ATCC)AMS Biotechnology Europe, Ltd. (AMSBIO)Applied Biological Materials, Inc. (ABM)Applied StemCell (ASC), Inc.Aruna Bio, Inc.Aspen Neuroscience, Inc.Axol Bioscience, Ltd.BD BiosciencesBeckman Coulter Life SciencesBioCat GmbHBlueRock TherapeuticsBrainXellCell Biolabs, Inc.Cell Signaling TechnologyCellariaCellGenix GmbHCellular Dynamics International, Inc.Cellular Engineering Technologies (CET)Censo Biotechnologies, Ltd.Century Therapeutics, LLCCiRACorning, Inc.Creative BioarrayCynata Therapeutics Ltd.Cytovia TherapeuticsDefiniGENEvotec SEFate Therapeutics, Inc.FUJIFILM Cellular Dynamics, Inc.GeneCopoeia, Inc.GenTarget, Inc.Heartseed, Inc.InvivoGeniPS Portal, Inc.iXCells BiotechnologiesLonza Group, Ltd.Megakaryon CorporationMerck/Sigma AldrichMetrion Biosciences, Ltd.Miltenyi Biotec B.V. & Co. KGNcardiaNeuCyteNewcells BiotechPancreatic MODY3PeproTechPhenocell SASPlatelet BioGenesisPluricell BiotechPromoCell GmbHQiagenR&D Systems, Inc.ReproCELLRHEINCELL Therapeutics GmbHStemina Biomarker DiscoverySynthego Corp.System Biosciences (SBI)Takara BioTakeda Pharmaceutical Co., Ltd.TEMCELL TechnologiesTempo BioscienceThermo Fisher Scientific, Inc.TreeFrog TherapeuticsVistaGen Therapeutics, Inc.Waisman BiomanufacturingxCell Science, Inc.Yashraj Biotechnology, Ltd. For more information about this report visit https://www.researchandmarkets.com/r/d2jcbt CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
13 April 2021 HARGREAVE HALE AIM VCT PLC (the “Company”) Allotment of Shares The Board announced on 2 September 2020 that the Company had published a prospectus in relation to an offer for subscription of ordinary shares of 1p each (the "Ordinary Shares"), to raise up to £20,000,000 (the "Offer"). The Board announced a Supplementary Prospectus on 8 January 2021. On 12 April 2021 the Company allotted 951,474 Ordinary Shares pursuant to the Offer. The offer price at which 951,474 Ordinary Shares were allotted was 99.18p per Ordinary Share, which was calculated, in accordance with the terms of the Offer, by reference to the net asset value of an Ordinary Share in the Company on 31 March 2021 (as announced on 7 April 2021, being the last published net asset value per Ordinary Share) divided by 0.965 (to allow for the costs of the Offer). Following this allotment, the total number of Ordinary Shares in issue is 231,409,173 with each Ordinary Share carrying one vote each. Therefore, the total voting rights in the Company are 231,409,173. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules. Application will shortly be made for the Ordinary Shares so allotted to be admitted to the Official List of the Financial Conduct Authority and to trading on the London Stock Exchange’s main market for listed securities, and dealings are expected to commence on or around the 16 April 2021. Definitive documents of title are expected to be despatched within 15 business days of allotment. Terms defined in the Prospectus have the same meaning where used in this announcement. END For further information, please contact: JTC (UK) LimitedSusan.FadilRuth WrightHHV.CoSec@jtcgroup.com +44 20 3893 1005 +44 203 893 1011 LEI: 213800LRYA19A69SIT31
Forecasts by Mission Type (Constellation Missions, Installation Missions, Replacement Missions), Investor Type (Venture Capital, Public/Private, Crowdfunding, Strategic/Private Equity, Traditional Investment, Government/Foundation), by Type (NanoSatellite, MicroSatellite, MiniSatellite, PicoSatellite, FemtoSatellite), by Application (IoT/M2M, Earth Observation & Meteorology, Military & Intelligence, Scientific Research & Exploration, Weather, Other Applications), by Industry (Satellite Services, Satellite Manufacturing, Launch Vehicles, Ground Equipment).New York, April 13, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Small Satellite Market Report 2020-2030" - https://www.reportlinker.com/p04694759/?utm_source=GNW PLUS, Analysis of Leading Small Satellite CompaniesGlobal small satellites market was valued at US$xx billion in 2019 and is projected to reach at a market value of US$xxbillion by 2030. North America market is expected to grow at a CAGR of xx% during the forecast period 2020-2030. The market is estimated to grow at a CAGR of xx% in the first half period 2020-2025 and is projected to grow at CAGR of xx% in the other half period 2025-2030. Small satellites (smallsats) are an emerging class of spacecraft that incorporates recent software and hardware improvements, most notably ones derived from the IT and electronics industries, and benefits from the resulting high capability feasible in small packages. There is no universally accepted definition of a smallsat; various groups and reports have classified smallsats according to their mass, volume, cost, capabilities, or some combination thereof. In this report, smallsats are defined as satellites with masses lower than 200 kg (with some exceptions). Small satellites include CubeSats, special types of cuboid-shaped smallsats that weigh between 1–10 kg, and are created in units of a 10 cm × 10 cm × 10 cm cube. Compared with traditional satellites, smallsats typically have shorter development cycles, smaller development teams, and, consequently, lower cost, both for the development and for the launch of the satellites. Almost all are planned for launch into LEO orbit; and over 60% will be CubeSats. The analyst used a scenario-based approach to identify key drivers propelling the development and direction of the smallsat sector. After an initial survey of current activities in the sector, the analyst selected four scenarios that could become reality 10–15 years from now. The analyst identified drivers that would lead to these end states, and examined their current status and trends. The analyst also assessed the likelihood of the scenarios coming to fruition between 2020 and 2030. This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today. Key Takeaways • Asia and Europe are strong players in the small satellite field, noted by stakeholders as having important markets and significant technological development • Asia in particular is noted as a growing region in the field, with new start-ups and increasing availability of launch. • Government is the primary source of funding in most emerging countries; although there is limited foreign private (venture capital) funding, such funding has not proliferated into the new space industry as widely as has occurred within the United States. • Countries with a longer space heritage, such as Russia, China, and potentially India, are often perceived as having not fully leveraged their satellite experience for small satellites, with government space programs having placed more emphasis on large satellites. However, this attitude is changing, particularly in China. • South American countries have demonstrated interest in small satellites given a growing number of government sponsored small satellite missions; Academic institutions are key in developing technologies. Market Segments Covered By Type • Mini-Satellite • Micro-Satellite • Nano-Satellite • Pico-Satellite • Femto-Satellite • Other Type By Industry • Satellite Services • Satellite Manufacturing • Launch Vehicles • Ground Equipment By Mission Type • Constellation Missions • Installation Missions • Replacement Missions By Application • IoT/M2M • Communication • Earth Observation & Meteorology • Military & Intelligence • Scientific Research & Exploration • Weather • Other Application Investor Type • Venture Capital • Public/Private • Crowdfunding • Strategic/Private Equity • Traditional Investment • Government/Foundation • Other Investor Types Leading Companies Profiled • Airbus SE • Park Aerospace Corp. • L3Harris Technologies, Inc. • Magellan Aerospace • Lockheed Martin • Maxar Technologies Inc. • Northrop Grumman • ORBCOMM Inc. • The Boeing Company • Thales Group • Dauria Aerospace • ISS Reshetnev • BAE Systems plc • Sierra Nevada Corporation • QinetiQ Group plc • OHB SE What does the future hold for the Small Satellite market? This new study supplies the answer to you and provides it to you NOW. In this new, 714-page report, you will receive 500+ tables and charts as well as independent, impartial, and objective analysis. By ordering and reading this report today, you will be given: • A concise and comprehensive analysis of the Small Satellite market from 2020 to 2030. • An understanding of not only the financial prospects of the Small Satellite industry but also the growth potential of several submarkets – including different application and end-user types. • An informed forecast of the sales of 25 individual countries – Australia, Brazil, Canada, China, France, Germany, India, Israel, Japan, Mexico, Russia, Saudi Arabia, South Korea, Spain, United Arab Emirates, United Kingdom and United States. • A description of the main drivers and restraints that are affecting the development of the Small Satellite market. • Profiles of the key players in the industry as well as up-to-date information on their latest agreements and CSI product developments. Who should read this report? • Senior Executives • Business Development Managers • Marketing Directors • Consultants • Chief Executive Officers • Governments, agencies & organisations actively working or interested in the Small Satellite industry will also find significant value in our research. Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight. This study is for everybody needing commercial analyses for the small satellite market and leading companies. You find data, trends and predictions.Read the full report: https://www.reportlinker.com/p04694759/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
Stryker (NYSE: SYK) acquired Mako Surgical in 2013. It did so with a plan to combine the company's leadership with Mako's innovative robotic arm assisted surgical products in an effort to transform orthopedics. In 2017, that plan came to fruition with what the company described as a first and only robotic arm assisted technology for total knee and hip replacement procedures.
(Bloomberg) -- Ukraine and Russia ratcheted up their rhetoric as U.S. Secretary of State Antony Blinken arrived in Brussels to discuss the escalating tensions with his European partners.Meeting with NATO chief Jens Stoltenberg, Ukrainian Foreign Minister Dmytro Kuleba said Russia, which has amassed troops near the two countries’ border, is threatening to destroy his country. Kremlin spokesman Dmitry Peskov said Russia poses no threat and urged Ukraine’s Western allies to stop it carrying out “provocative actions.”The region is on edge over a Russian military buildup in recent weeks around the conflict that began after President Vladimir Putin annexed Crimea in 2014. With Putin’s intentions unclear, the fear is that even a low-level skirmish could reignite more serious fighting. The war over the status of two breakaway regions in Ukraine’s east has already cost more than 13,000 lives.“Russia has to understand that Ukraine belongs to the world of democracies, to the Western world -- this is the very clear message NATO can send to Russia,” Kuleba said. “Ukraine isn’t part of the Russian world and will never be considered as such.”NATO joined the Group of Seven nations and the European Union in calling for Russia to de-escalate. The G-7 and the EU said earlier that they’re “deeply concerned” about Russia’s build-up of forces.“These large-scale troop movements, without prior notification, represent threatening and destabilizing activities,” they said in a joint statement. “We call on Russia to cease its provocations and to immediately de-escalate tensions in line with its international obligations.”The Kremlin, which accuses its neighbor of planning a new military offensive to take back the Russian-speaking Donbas region, on Tuesday called the U.S.’s deployment of warships to the nearby Black Sea in solidarity with Ukraine “extremely provocative.” Blinken warned at the weekend of consequences if Russia acts recklessly or aggressively.“Any threat only reinforces our conviction that we’re conducting the right policy,” Russian Deputy Foreign Minister Sergei Ryabkov told reporters. “We’re just defending our interests and the interests of our citizens, the Russian-speaking population. We’ll continue to defend them.”Despite Ukraine repeatedly rejecting any suggestion it’s planning a new military operation, Russian state television -- which dominates the airwaves at home and in Donbas -- is playing up the chances of an attack. Confusion continues to surround Putin’s goals in the region, with the threat of more Western sanctions growing if he makes a move to tighten control over the breakaway regions.Diplomacy to head off a resumption of large-scale fighting that was ended by a 2015 peace accord is continuing apace. Aside from Blinken’s meetings in the Belgian capital, U.S. Defense Secretary Lloyd Austin is holding talks with his opposite number in Berlin.Concern over fresh sanctions sent the ruble to its lowest level against the dollar since November last week, though it edged higher on Tuesday. The tensions are taking a toll on Ukrainian assets, with the yield on the government’s dollar bond due 2026 hitting its highest since November.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Japan is facing opposition for the decision from local fishing industry and neighbours including China
Dublin, April 13, 2021 (GLOBE NEWSWIRE) -- The "Global Hydrogen Electrolyzer Market (Value, Volume) - Analysis By Product, Application, By Region, By Country (2021 Edition): Market Insights, Covid-19 Impact, Competition and Forecast (2021-2026)" report has been added to ResearchAndMarkets.com's offering. Increasing demand for highly efficient and low-space utilizing energy storage systems to handle the electricity produced from solar, wind and hydropower generation units are primary factors driving the global hydrogen electrolyzers market during forecast period. Moreover, increasing establishments of renewable power generation units across the globe coupled with growing investments by the organization in future sustainable technologies are contributing to the growth of hydrogen electrolyzer market during forecast period.Among the Product segment in the Hydrogen Electrolyzer market (Proton Exchange Membrane Electrolyzer, Alkaline Electrolyzer and Solid Oxide Electrolyzer), Alkaline Electrolyzer segment leads the market. Alkaline electrolyzer operate by the principle of transportation of hydroxide ions via the electrolyte. These are transferred from the cathode to the anode, while hydrogen is generated on the cathode side during the process. These electrolyzer use potassium or sodium hydroxide based liquid alkaline solution as an electrolyte. This type of electrolyzer is supplied by many companies, such as Tianjin Mainland Hydrogen Equipment Co., Ltd. (THE), one of the leading suppliers of this equipment.Based on Application (Power Plants, Energy Storage, Industrial Gases, Power to Gas and Others), Power Plants segment gains a considerable share. Electrolyzers are mainly used for the production of hydrogen with the help of electrolysis of water. They are widely used in the automotive industry for fuel cell electric vehicles as hydrogen can store large amounts of energy and release it when needed for industrial use.The North America Region dominates the Hydrogen Electrolyzer market. In North America, collective government investments to boost the activities of renewable energy production units and decrease the production of electricity from coal-powered stations is expected to boost huge market demand for hydrogen electrolyzer during forecast period.Key Target Audience Hydrogen Electrolyzer CompaniesInvestors/Investment BankersDistributorsGovernment and Research OrganizationsAssociations and Industry Bodies Key Topics Covered: 1. Report Scope and Methodology1.1 Scope of the Report1.2 Research Methodology1.3 Executive Summary2. Strategic Recommendations3. Global Hydrogen Electrolyzer Market: Product Outlook4. Global Hydrogen Electrolyzer Market: An Analysis4.1 Market Size, By Value, Year 2016-20264.2 Market Size, By Volume, Year 2016-20264.3 Market Growth Rate, Year 2016-20265. Global Hydrogen Electrolyzer Market Segmentation By Product (By Value, By Volume)5.1 Competitive Scenario of Global Hydrogen Electrolyzer Market: By Product5.2 Proton Exchange Membrane Electrolyzer- Market Size and Forecast (2016-2026)5.3 Alkaline Electrolyzer- Market Size and Forecast (2016-2026)5.4 Solid Oxide Electrolyzer- Market Size and Forecast (2016-2026)6. Global Hydrogen Electrolyzer Market Segmentation By Application (By Value, By Volume)6.1 Competitive Scenario of Global Hydrogen Electrolyzer Market: By Application6.2 Power Plants- Market Size and Forecast (2016-2026)6.3 Energy Storage- Market Size and Forecast (2016-2026)6.4 Industrial Gases- Market Size and Forecast (2016-2026)6.5 Power to Gas- Market Size and Forecast (2016-2026)6.6 Others- Market Size and Forecast (2016-2026)7. Global Hydrogen Electrolyzer Market: Regional Analysis7.1 Competitive Scenario of Global Hydrogen Electrolyzer Market: By Region8. North America Hydrogen Electrolyzer Market (Value, Volume): An Analysis (2016-2026)9. Europe Hydrogen Electrolyzer Market (Value, Volume): An Analysis (2016-2026)10. Asia Pacific Hydrogen Electrolyzer Market (Value, Volume): An Analysis (2016-2026)11. Global Hydrogen Electrolyzer Market Dynamics11.1 Global Hydrogen Electrolyzer Market Drivers11.2 Global Hydrogen Electrolyzer Market Restraints11.3 Global Hydrogen Electrolyzer Market Trends12. Market Attractiveness and Strategic Analysis12.1 Market Attractiveness12.1.1 Market Attractiveness Chart of Global Hydrogen Electrolyzer Market - By Product, By Value (Year-2026)12.1.2 Market Attractiveness Chart of Global Hydrogen Electrolyzer Market - By Application, By Value (Year-2026)12.1.3 Market Attractiveness Chart of Global Hydrogen Electrolyzer Market - By Region, By Value (Year-2026)12.2 Strategic Analysis12.2.1 Mergers and Acquisitions12.2.2 Recent Industry Developments13. Competitive Landscape13.1 Market Share Analysis13.2 Competitive Positioning (Leaders, Challengers, Followers, Niche Players)14. Company Profiles (Business Description, Financial Analysis, Business Strategy)14.1 Nel Hydrogen14.2 Hydrogenics14.3 Mcphy14.4 ITM Power14.5 Plug Power14.6 Giner, Inc.14.7 AREVA H2Gen14.8 ERGOSUP14.9 Green Hydrogen Systems14.10 Loop Energy Inc.For more information about this report visit https://www.researchandmarkets.com/r/6p5sr1 CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Top news and what to watch in the markets on Tuesday, April 13, 2021.
Growth in Leading Regional and National Markets (North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America, US, Canada, Germany, France, UK, Italy, Spain, India, China, Australia, South Korea, Japan, South Africa, Saudi Arabia, U.New York, April 13, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Generic Drugs Market Report 2020-2030" - https://www.reportlinker.com/p04753860/?utm_source=GNW A.E, Brazil, Argentina, Mexico, Teva, Novartis, Mylan, Pfizer, Abbott, Sun Pharma, Aspen, Fresenius Kabi, Sanofi, Dr. Reddy’s Laboratories Limited, Apotex)The global generic drugs market is estimated at US$xyz billion in 2020 and is projected to reach at a CAGR of xyz% during forecast period 2020-2030 to grow at a market value of US$xyz billion by 2030, taking into account assumptions for V-shaped economic conditions. The increase in healthcare expenditure and a rise in the cost of pharmaceuticals worldwide results in a strained national budget due to which a high proportion of people are not able to access to essential medications. As per the World Health Organization (WHO), approximately 30% of the world’s population lack access to essential medicines. The main factor that hampers access to these medicines is the cost of these pharmaceutical drugs. The robust growth of the pharmaceutical market and increase in the share of total healthcare spending have reignited the age-old debate on how to balance the cost of innovation in drug research and grant universal access to that research. Reduction in healthcare expenditure by generic medicines has been acknowledged for a long time. Multiple studies have proven that substituting the brand name drugs with cheaper generic medicines can prove to save about 10-90% of the cost spent on the preparation of these medicines. Government initiatives like reimbursement policies have further encouraged the use of generic drugs and this policy has led the adoption of using generic medicines as a substitute over expensive branded original medications by various healthcare systems. This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today. Market Driving Forces • Emerging market: This factor has a direct link with the growth of the geographical generic drug market. So, with the emergence of new generic markets, the competition for generic drugs is increasing because of which various regions and companies are competing to increase their sales of generic drugs in the market. • Awareness and advance healthcare systems: Earlier, people, as well as the doctors, were not quite aware of the use of generic drugs but after the introduction of generic drugs, companies and organizations have come up with workshops, conferences and training to promote the idea of generic drugs so that, people could be well-aware of its use. • Cost-effectiveness and increasing investments: The cost of generic drugs is quite cheap as compared to the brand-name drugs which have increased the sales of generic drugs in the market. As the cost of these drugs is affordable so, many companies have started investing in manufacturing the generic drugs. • Increase of chronic diseases and the ageing population: This is one of the most important factors that contribute to driving the sales of generic drugs. How this report will benefit you In this brand new 431-page report you will receive 66 tables and 287 figures– all unavailable elsewhere. The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market. By ordering and reading our brand-new report today you stay better informed and ready to act. Report Scope • Generic Drugs Market by Drug Delivery forecasts from 2020-2030 • Oral • Dermal/Topical • Inhalants • Injectable • Generic Drugs Market by Distribution Channel forecasts from 2020-2030 • Hospital Pharmacy • Retail Pharmacy Generic Drugs Market by Application forecasts from 2020-2030 • Oncology • Diabetes • Autoimmune • Other Application • Generic Drugs Market forecasts from 2020-2030 by Regional and National Market: • North America: U.S., Canada • Europe: Germany, France, UK, Italy, Spain, Rest of Europe • Asia-Pacific: Japan, China, Australia, South Korea, India, Rest of Asia-Pacific • Middle East & Africa: South Africa, Saudi Arabia, UAE, Rest of Middle east & Africa • Latin America: Brazil, Argentina, Mexico, Rest of Latin America The global generic drugs market is estimated at US$xyz billion in 2020 and is projected to reach at a CAGR of xyz% during forecast period 2020-2030 to grow at a market value of US$xyz billion by 2030, taking into account assumptions for V-shaped economic conditions. • Profiles and generic drugs revenue forecasts from 2020-2030 of these selected leading companies: • Abbott • Apotex • Aspen • Dr. Reddy’s Laboratories Limited • Fresenius Kabi • Mylan • Novartis • Pfizer • Sanofi • Sun Pharma • Teva • Taisho Pharmaceutical Holdings Co Ltd • ASKA Pharmaceutical Co., Ltd. • H. Lundbeck A/S • Roche Holding • Qualitative analysis of the generic drugs market: • SWOT Analysis of the generic drugs market • Porter’s Five Forces Analysis of the generic drugs market • Discussion on factors that drive and restrain the generic drugs market • Key Questions Answered by This Report: • How is the global market for generic drugs evolving? • What are the major factors driving and restraining the generic drugs market dynamics? • What were the market shares of the leading national markets in the global generic drugs market in 2019? • How will each of these national markets grow over the forecast period and how much revenue will these markets account for by 2030? • How will the market shares for each of the national markets develop from 2020 to 2030? • Which particular national markets will be the main drivers of growth in the global market for generics from 2020 to 2030? • How will political and regulatory factors influence the regional markets and submarkets? • What are the predictions for partnerships, consolidation for existing players and the potential prospects for new market entrants? • How will the industry sector evolve as legislations around patents and patent expiries change during the period between 2020 and 2030? This study is intended for anyone requiring commercial analyses for the Generic Drugs Market. You find data, trends and predictions.Read the full report: https://www.reportlinker.com/p04753860/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
After more than a year, arguably the stock market's most persistent concern has returned: inflation. One of the safest ways to run circles around inflation over the long run is to buy into brand-name utility stocks.
Investment bank JPMorgan recommended selling emerging market currencies on Tuesday, completing a 180-degree pivot from the start of the year when it was backing them to have a good run. After forecasts of a strong run for emerging currencies at the start of the year, many big banks have since turned more bearish as rising U.S. rates, COVID-19 worries and idiosyncratic risks besetting Turkey and Russia weigh on sentiment. MSCI's index of emerging market currencies was down around 2% from levels hit two months ago.
Kanye West has reportedly requested joint custody of his four children with Kim Kardashian West as the couple’s divorce proceedings continue. The papers reportedly show that West, 43, requests joint legal and physical custody of his children - daughters North, 7, and Chicago, 3, and sons Saint, 5, and Psalm, who is almost 2. West does not request spousal support.
‘Behind the cars. Now! Now!’ shouted someone off-camera
Dublin, April 13, 2021 (GLOBE NEWSWIRE) -- The "COVID-19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Medical Devices Pipeline Assessment, 2020" report has been added to ResearchAndMarkets.com's offering. "COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.COVID 19 EIA/ELISA are the most widely used assays having high sensitivity and specificity. They are used to detect the recombinant protein and peptide antigens in the samples. ELISA's are specifically designed to screen large number of samples at a time.Scope Extensive coverage of the COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) under developmentThe report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activitiesThe report reviews the major players involved in the development of COVID 19 Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) and list all their pipeline projectsThe coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stageThe report provides key clinical trial data of ongoing trials specific to pipeline productsRecent developments in the segment / industry Reasons to Buy Formulate significant competitor information, analysis, and insights to improve R&D strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantageDevelop market-entry and market expansion strategiesPlan mergers and acquisitions effectively by identifying major players with the most promising pipelineIn-depth analysis of the product's current stage of development, territory and estimated launch date Key Topics Covered: 1 Table of Contents2. Introduction 3 Products under Development Pipeline Products by Stage of DevelopmentPipeline Products by TerritoryPipeline Products by Regulatory PathPipeline Products by Estimated Approval DateOngoing Clinical Trials 4 Pipeline Products under Development by Companies & Stage of Development 5 Companies and Product Overview 20/20 GeneSystems IncAbbott DiagnosticsAbbott LaboratoriesAbsology Co LtdAbwiz Bio IncAchira Labs Pvt LtdADiTx Therapeutics IncADMA Biologics IncAegirBio ABAegis Sciences CorpAESKU Diagnostics GmbH & Co KGALPCO DiagnosticsAnhui Deep Blue Medical Technology Co LtdAnsh Labs LLCArrayit CorporationARUP LaboratoriesAvacta Group PlcAxim Biotechnologies IncAxium BioResearch IncBabson Diagnostics IncBase10 Genetics IncBeckman Coulter IncBeijing Shengkun Kangru Medical Equipment Co LtdBen-Gurion University of the NegevBio Techne CorpBiohit Healthcare LtdBioIQ IncBiolinker Synthetic Biology LtdBiomerica IncBloom Diagnostics AGBreviTest Technologies LLCCalviri IncCareHealth America CorpCellmid LtdClinomics IncCore Technology Co LtdDiabetOmics IncDiaCarta IncDiagnostics Biochem Canada IncDIALAB GmbHDiaSorin IncDLS Research and VenturesDRG International IncEDP Biotech CorporationEmpower Clinics IncEnable Biosciences IncEnzo Biochem IncEpigentek Group IncEpitope Diagnostics, Inc.Erba MannheimEurofins Scientific SEEuroimmun AGExcelsior Bio-Systems IncEzra AI IncFujirebio Diagnostics IncGauss Surgical IncGeneral Biologicals CorpGenspeed Biotech GmbhHecin Scientific IncIcosagen ASIDvetImmunodiagnostics LtdImmunoPrecise Antibodies LtdIndian Institute of Technology GuwahatiInterpace Biosciences IncKantaro Biosciences LLCKephera Diagnostics LLCKRISHGEN BioSystemsLansion Biotechnology Co LtdLeadgene Biomedical IncLeinco Technologies IncLumos Diagnostics IncMaxim Biomedical IncModule Innovations Pvt LtdMologic LtdMonarch Global Health LLCMonopar Therapeutics IncNanjing Liming Bio-Products Co LtdNeurix SANirmidas Biotech IncNorthwestern UniversityNovaTec Immundiagnostica GmbHNovo Nordisk ASOraSure Technologies IncOrtho-Clinical Diagnostics IncOy Medix Biochemica AbPepex Biomedical, Inc.PerkinElmer IncPhadia ABPinnacle BioLabsPrantae Solutions Pvt LtdPremier Medical CorporationProGnosis Biotech SAPromega CorpProMIS Neurosciences IncQiagen NVQlife Holding ABQuanterix CorpRoche Diagnostics International LtdSafetest Comercio de Diagnosticos LtdSciteck Diagnostics IncShenzhen Kingfocus Biomedical Engineering Co LtdShenzhen Tisenc Medical Devices Co LtdShijiazhuang Hipro Biotechnology Co LtdSiemens Healthcare Diagnostics IncSiemens Healthineers AGSQI Diagnostics IncSt Petersburg Research Institute of Vaccines and SeraStream Bio LtdSyngeneSysmex CorpTaizhou ZECEN Biotech Co LtdThe Binding Site IncThe Johns Hopkins Bloomberg School of Public HealthThermoGenesis Holdings IncTrinity Biotech PlcUniversity of MelbourneVidaCheck LLCVivera Pharmaceuticals IncVyriad IncWest Virginia University School of MedicineZalgen Labs LLCZandcell ABZEUS Scientific Inc 6 Recent Developments Oct 07, 2020: For COVID-19 detection and epidemiology, xMAP technology offers unique advantagesMay 28, 2020: GeneTex releases high-affinity recombinant monoclonal antibodies to accelerate SARS-CoV-2 researchApr 15, 2020: Todos Medical achieves medical importer status with US FDAMar 24, 2020: Helping expand COVID-19 antibody testing capacity 7 Appendix For more information about this report visit https://www.researchandmarkets.com/r/xb0tn3 CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900